Imaging Immune Activation in HIV by PET-MR (NCT03684655)
Imaging Immune Activation in HIV Infection
๐ฉบ Plain-English Summary (8th-Grade Level)
This is a single center exploratory imaging study involving one intravenous microdose of \[18F\]F-AraG followed by whole-body positron emission tomography-magnetic resonance (PET-MR) imaging in HIV infected individuals to determine the anatomical distribution of the PET tracer. Participants will be enrolled if they were treated during early or late HIV infection. In addition, individuals not on antiretroviral therapy (ART) or with HIV-1 plasma RNA levels \>5,000 copies/mL will be enrolled. Up to 30 participants will be enrolled with HIV.
Who can join: Review the eligibility criteria below.
Location: University of California, San Francisco โ San Francisco, California
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- University of California, San Francisco โ San Francisco, California
๐ Contact the Study Coordinator
Phone: (415) 206-5518
Email: timothy.henrich@ucsf.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HIV Infections
- Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention โ Chicago, Illinois
- The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City โ New York, New York
- Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults โ Birmingham, Alabama
- Clinical Decision Support for PrEP โ Los Angeles, California
- Peer Supported Collaborative Care Mental Health and Substance Use Disorder Care โ Baltimore, Maryland
- A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV โ Las Vegas, Nevada
Explore by condition: All HIV Infections clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.